GeoVax Labs CFO Mark W. Reynolds Resigns; Anna Skowron Appointed as Successor
GeoVax Labs has appointed Anna Skowron as Chief Financial Officer, effective November 16, 2026, following the resignation of Mark W. Reynolds from all officer positions.
GeoVax Labs, Inc., a clinical-stage biotechnology company based in Smyrna, Georgia, has announced several leadership changes across its senior management team. Mark W. Reynolds resigned from all his officer roles on November 13, 2026, including Chief Financial Officer, Corporate Secretary, Principal Financial Officer and Principal Accounting Officer. The company did not disclose a reason for his departure.
Following his resignation, the Board of Directors appointed Anna Skowron as CFO on November 14, 2026, with her appointment taking effect on November 16, 2026.
Skowron, 39, has served as a Director of BPC Consulting Ltd. since September 2025. She also holds fractional CFO positions at GridAI Technologies Corp. since March 7, 2025, Powell Max Limited since February 9, 2026 and BioRestorative Therapies, Inc. since August 2026. Previously, she served as Principal of Skowron Accounting Professional Corporation from 2020 through June 2026.
Under the CFO Consulting Agreement with BPC Consulting Ltd., Skowron will oversee accounting and financial reporting, including the preparation of periodic regulatory filings. She will report to the Chief Executive Officer and the Chairman of the Audit Committee. BPC is also eligible for a performance-based bonus upon successful completion of the annual Form 10-K and related year-end audit, with the amount to be mutually agreed upon before the audit begins.
In a separate leadership change, GeoVax Labs confirmed the termination of Chief Medical Officer Kelly T. McKee, M.D., effective immediately on November 17, 2026. No further details regarding the termination were disclosed.
Skowron holds a Bachelor of Commerce degree from the University of Toronto, with a Specialist in Accounting and a Major in Economics.
